Press Releases

Nov 12, 2014 • 7:35 AM EST Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001

Nov 10, 2014 • 7:35 AM EST Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001

Nov 4, 2014 • 7:35 AM EST Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board

Oct 29, 2014 • 7:35 AM EDT Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001

Oct 20, 2014 • 8:05 AM EDT Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia

Sep 30, 2014 • 7:35 AM EDT Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014

Sep 8, 2014 • 7:05 AM EDT Matinas BioPharma Holdings, Inc. Approved to Trade on OTCQB Venture Stage Marketplace

Sep 4, 2014 • 7:05 AM EDT Matinas BioPharma to Present at Three Investor Conferences in September

Jul 31, 2014 • 8:05 AM EDT Matinas BioPharma Launches Digital Corporate Communication Channels

Jul 22, 2014 • 8:15 AM EDT Matinas BioPharma Holdings, Inc. Common Stock Commences Trading on OTCBB Under Ticker Symbol MTNB